Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Anixa Biosciences Inc
ANIX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.68
0.07
2.68%
Dern. MÀJ: Oct 20, 4:33 PM
$2.78
0.17
6.51%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Anixa Biosciences Financials
Anixa Biosciences (ANIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Benzinga Newsdesk
PRO
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 30 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
Anixa Biosciences Highlights 2024 Achievements And 2025 Goals: Utilized $7M, Ended With $20M Cash, Presented Phase 1 Breast Cancer Vaccine Data With 70% Immune Response, Advanced Ovarian Cancer CAR-T Program, Preparing Phase 2 Study And Broader Cancer Vaccine Development
Benzinga Newsdesk
Recap: Anixa Biosciences Q1 Earnings
Benzinga Insights
Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.41% to 34,060.60 while the NASDAQ fell 1.08% to 13,900.17. The S&P also fell, dropping 0.59% to 4,160.89.
Lisa Levin
